{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:45:32Z","timestamp":1784634332832,"version":"3.55.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/cco.0000000000000009","type":"journal-article","created":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T15:49:08Z","timestamp":1381160948000},"page":"701-706","source":"Crossref","is-referenced-by-count":22,"title":["Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia"],"prefix":"10.1097","volume":"25","author":[{"given":"Dieter","family":"Hoelzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20210128","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia.","volume":"29","author":"Bassan","year":"2011","journal-title":"J Clin Oncol"},{"key":"R2-18-20210128","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cncr.24862","article-title":"Adult acute lymphoblastic leukemia: concepts and strategies.","volume":"116","author":"Faderl","year":"2010","journal-title":"Cancer"},{"key":"R3-18-20210128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.blre.2011.08.001","article-title":"Chemoimmunotherapy in acute lymphoblastic leukemia.","volume":"26","author":"Hoelzer","year":"2012","journal-title":"Blood Rev"},{"key":"R4-18-20210128","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1200\/JCO.2012.41.6768","article-title":"Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"key":"R5-18-20210128","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R6-18-20210128","first-page":"abstract481","article-title":"Immunochemotherapy with rituximab in adult CD20 B-precusor ALL improves molecular CR rate and outcome in standard risk (SR) as well as in high risk (HR) patients with SCT.","volume":"94","author":"Hoelzer","year":"2009","journal-title":"Haematologica"},{"key":"R7-18-20210128","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"key":"R8-18-20210128","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1182\/blood.V104.11.2732.2732","article-title":"Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia (ALL) abstract.","volume":"104","author":"Hoelzer","year":"2004","journal-title":"Blood"},{"key":"R9-18-20210128","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/pbc.22209","article-title":"A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Childrens Oncology Group report.","volume":"53","author":"Angiolillo","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R10-18-20210128","first-page":"2603","article-title":"Southwest Oncology Group Study S0910: a phase 2 trial of clofarabinecytarabineepratuzumab for relapsedrefractory acute lymphocytic leukemia.","volume":"120","author":"Advani","year":"2012","journal-title":"ASH (Annual Meeting Abstracts)"},{"key":"R11-18-20210128","first-page":"248","article-title":"A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL).","volume":"118","author":"Wayne Alan","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R12-18-20210128","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"key":"R13-18-20210128","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.","volume":"120","author":"Gokbuget","year":"2012","journal-title":"Blood"},{"key":"R14-18-20210128","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"R15-18-20210128","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"R16-18-20210128","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"R17-18-20210128","first-page":"670","article-title":"Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsedrefractory B-precursor acute lymphoblastic leukemia (ALL).","volume":"120","author":"Topp","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R18-18-20210128","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19CD3-bispecific BiTE antibody blinatumomab.","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"R19-18-20210128","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/leu.2010.239","article-title":"Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with posttransplant relapsed acute lymphoblastic leukemia.","volume":"25","author":"Handgretinger","year":"2011","journal-title":"Leukemia"},{"key":"R20-18-20210128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/14653249.2011.613931","article-title":"The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.","volume":"14","author":"Rettinger","year":"2012","journal-title":"Cytotherapy"},{"key":"R21-18-20210128","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/bmt.2011.202","article-title":"The antitumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies.","volume":"47","author":"Linn","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"R22-18-20210128","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"R23-18-20210128","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:54:40Z","timestamp":1620950080000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201311000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000009","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}